530991 Stock Overview
Manufactures, markets, and sells bulk drugs and intermediaries in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Roopa Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹75.73 |
| 52 Week High | ₹114.90 |
| 52 Week Low | ₹43.00 |
| Beta | -0.48 |
| 11 Month Change | -17.48% |
| 3 Month Change | 4.99% |
| 1 Year Change | 66.37% |
| 33 Year Change | 317.25% |
| 5 Year Change | 801.55% |
| Change since IPO | 1,109.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 530991 | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -12.3% | -0.8% | 0.5% |
| 1Y | 66.4% | 10.7% | 27.5% |
Return vs Industry: 530991 exceeded the Indian Chemicals industry which returned 10.7% over the past year.
Return vs Market: 530991 exceeded the Indian Market which returned 27.5% over the past year.
Price Volatility
| 530991 volatility | |
|---|---|
| 530991 Average Weekly Movement | 11.2% |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 530991's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 530991's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 55 | Tumbalam Raghavendra | www.investorsatril.com |
Roopa Industries Limited manufactures, markets, and sells bulk drugs and intermediaries in India and internationally. The company offers triphenylphosphine, abacavir sulphate, d-penicillamine, s-octabase, DCC, and DPA 3. It manufactures and exports glucosamine.
Roopa Industries Limited Fundamentals Summary
| 530991 fundamental statistics | |
|---|---|
| Market cap | ₹595.66m |
| Earnings (TTM) | ₹15.78m |
| Revenue (TTM) | ₹1.02b |
37.7x
P/E Ratio0.6x
P/S RatioIs 530991 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530991 income statement (TTM) | |
|---|---|
| Revenue | ₹1.02b |
| Cost of Revenue | ₹881.51m |
| Gross Profit | ₹142.56m |
| Other Expenses | ₹126.78m |
| Earnings | ₹15.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.01 |
| Gross Margin | 13.92% |
| Net Profit Margin | 1.54% |
| Debt/Equity Ratio | 167.9% |
How did 530991 perform over the long term?
See historical performance and comparison